Bär & Karrer advised Netrics Group, a portfolio company of funds advised by Bregal Unternehmerkapital, on Garaio’s majority stake acquisition, Kellerhals Carrard advised Garaio’s shareholders on the transaction. Garaio is a swiss
Vischer advised BID Equity on Realview’s acquisition, a developer and software distributor for the Swiss construction industry. Founded in 2013 and based in Zurich, Realview, with it stried-and-tested software solutions, operates a decisive contribution to
by claudia la via Guido Wennemer, Acer’s Emea General Counsel, highlights the complex interplaybetween innovation, regulation, and legal practice in the technology sector. The technology sector is rapidly evolving and this poses significant legal
Bratschi advised the shareholders of Mental Capital, an asset manager based in Lucerne, on its acquisition by Colombo Wealth. The team M&A partner Etienne Gard (pictured left) and tax partner Michael Barrot (pictured
Wenger Vieli advised Alturos Destinations, a provider of tourism technology solutions, on all Swiss legal and tax matters during the sale to Juniper Group. The funds will support Alturos’ growth and expand its international market
On 23 May 2024, Houzy AG announced that Houzy and Devis.ch SA are merging. Walder Wyss advised Houzy Corporate/M&A with a team led by managing associates Dario Galli (pictured left) and Michael Kü
by claudia la via In 2024, the Swiss M&A landscape is predicted to see a robust recovery, marking a stark contrast from the cautious approach witnessed in 2023. As companies align with more stable economic
Kontivia Beteiligungen, a Zurich based long term oriented investment firm advised by Kellerhals Carrard, led a group of swiss entrepreneurial families, advised by Baker McKenzie, in the acquisition of a majority stake in Walter Meier (
Boris Zaïtra (pictured), currently head of group business development, will be appointed as head of corporate business development, effective 1 july 2024. James Sabry, head of Roche Pharma Partnering, will be retiring after fourteen years in
Walder Wyss advised SixPeaks Bio in securing USD 30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca. The latter, advised by Lenz & Staehelin, will provide additional,
